Simplifying Global Compliance
The QMN Weekly Bulletin
Pharmaceuticals / Commercial Operations
Eli Lilly Sues Actavis to Halt Generic Axiron ANDA
Dec. 20, 2013
Eli Lilly and Acrux on Nov. 12 filed suit against Actavis to prevent the generic drugmaker from commercializing a generic version of the testosterone topical solution Axiron. The lawsuit, filed in the U.S. District Court for the Southern District of Indiana, will delay any FDA approval of Actavis’ ANDA for up to 30 months or until the court resolves the suit.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing